Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Average Rating of “Moderate Buy” by Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $51.00.

COLL has been the subject of several analyst reports. Needham & Company LLC lowered their price objective on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Barclays decreased their price target on Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, August 19th. Wall Street Zen downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Finally, Zacks Research cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL traded up $0.17 during mid-day trading on Monday, hitting $27.29. 102,059 shares of the company’s stock traded hands, compared to its average volume of 509,012. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. Collegium Pharmaceutical has a 1 year low of $25.47 and a 1 year high of $50.79. The company’s 50-day moving average is $33.67 and its two-hundred day moving average is $35.70. The company has a market capitalization of $888.29 million, a P/E ratio of 22.00 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The company had revenue of $199.88 million during the quarter, compared to analyst estimates of $199.62 million. During the same quarter last year, the business posted $1.68 earnings per share. The firm’s revenue was up 6.3% on a year-over-year basis. On average, equities analysts anticipate that Collegium Pharmaceutical will post 6.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the company. Group One Trading LLC purchased a new position in shares of Collegium Pharmaceutical during the fourth quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 427 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 418 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 318 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.